- Telo Genomics (TELO) has appointed Kris Weinberg as Chief Executive Officer of the company, effective today
- Weinberg has hands-on experience in the field of high-value molecular testing, with a focus on the commercialization of innovative oncology technologies
- Telo Genomics is a biotech company which develops diagnostic and prognostic products for cancer and neurological disorders
- Telo Genomics Corp. (TELO) is up 14.29 per cent, trading at C$0.40 per share at 12:16 pm ET
Telo Genomics (TELO) has appointed Kris Weinberg as Chief Executive Officer of the company, effective today.
Weinberg will replace the current CEO, Sherif Louis, Ph.D., who will assume the position of President & Chief Technology Officer.
Weinberg is an accomplished industry veteran and commercial leader. He has hands-on experience in the field of high-value molecular testing, with a focus on the commercialization of innovative oncology technologies.
He has most recently led the commercial activities at Theralink Technologies. In this role, he successfully launched the Theralink Assay for Breast Cancer to physicians and payors nationally in the US. Previously, Weinberg held commercial leadership roles at Natera, Guardant Health, Biodesix and Genomic Health, where he was successful in launching innovative cancer tests across multiple platforms.
John Meekison, the Board Director & Chair of the Audit Committee at Telo Genomics, commented on the appointment.
“These executive changes are integral to TELO’s long-term growth strategy. Sherif has spearheaded the company’s technology turn-around with the successful development of the Telo multiple myeloma (Telo-MM) tests. We look forward to working with both Sherif and Kris as the company progresses with the commercialization of Telo-MM, moving from lab to clinic.”
Telo has completed the clinical validation of two tests developed to address important unmet clinical needs in the management of Multiple Myeloma (MM). The lead product identifies high-risk smouldering multiple myeloma patients who are likely to benefit from earlier treatment intervention. The second MM assay predicts treatment resistance in newly diagnosed MM patients. Identifying these patients allows physicians to modify their treatment regimens in a timely manner.
Telo Genomics is a biotech company which develops diagnostic and prognostic products for cancer and neurological disorders.
Telo Genomics Corp. (TELO) is up 14.29 per cent, trading at C$0.40 per share at 12:16 pm ET.
